Opinion

Video

Challenges With Defining “Ruxolitinib Failure” or Suboptimal Response to Ruxolitinib in MF

Author(s):

Andrew Kuykendall, MD,Venu Konala, MD

Panelists discuss how they define “ruxolitinib failure” and a suboptimal response, when they consider switching from first-line ruxolitinib, and how they differentiate between myelofibrosis-induced and JAK-induced cytopenias.

  1. Dr Kuykendall to Dr Konala: Switching gears a bit, Dr Konala: How do you define “ruxolitinib failure?” What is a suboptimal response, in your clinical opinion?
  2. Dr Kuykendall: Please comment on your threshold or when you might consider switching from first-line ruxolitinib and how you differentiate myelofibrosis-induced cytopenias (anemia or thrombocytopenia) from JAK-induced cytopenias.
Related Videos
Related Content